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Summary The C017-1A/GA733 antigen is associated with human carcinomas and some normal epithelial tissues. This antigen has shown
promise as a target in approaches to passive and active immunotherapy of colorectal cancer. The relevance of animal models for studies
of immunotherapy targeting this antigen in patients is dependent on the expression of the antigen on normal animal tissues.
Immunohistoperoxidase staining with polyclonal rabbit antibodies to the human antigen revealed the human homologue on normal small
intestine, colon and liver of mice, rats and non-human primates, whereas mouse monoclonal antibodies to the C017-1A or GA733 epitopes
on the human antigen did not detect the antigen. Polyclonal rabbit antibodies, elicited by the murine antigen homologue derived from
recombinant baculovirus-infected insect cells, immunoprecipitated the antigen from mouse small intestine, colon, stomach, kidney and lung.
The isolated recombinant murine protein bound polyclonal, but not monoclonal, antibodies to the human C017-1A/GA733 antigen, and
recombinant human antigen bound polyclonal antibodies elicited by the murine antigen homologue. Thus, the antigen homologue expressed
by animal tissues is similar, but not identical, to the human antigen. These results have important implications for experimental active and
passive immunotherapy targeting the C017-1A/GA733 antigen.
Keywords: colorectal carcinoma; C017-1A/GA733 antigen homologue; murine epithelial glycoprotein; experimental animals
The C017-lA/GA733 antigen (referred to hereafter as GA733
antigen) is a glycoprotein associated with human epithelial carci-
nomas with an apparent molecular mass of40 kDa as determined
electrophoretically. The antigen was originally defined using
monoclonal antibodies (MAbs) CO17-lA (Herlyn et al, 1979),
GA733 (Herlyn et al, 1984) and M77 (Gottlinger et al, 1986),
which bind to different epitopes on the protein core ofthe antigen.
The antigen has been molecularly cloned (GA733-2) (Szala et al,
1990). The GA733-2 cDNA sequence is nearly identical with the
KS 1/4 (Perez and Walker, 1989; Strnad et al, 1989) and HEA 125
cDNA sequences (Simon et al, 1990), which encode 42-40 kDa
and 34-kDa epithelial cell surface glycoproteins respectively.
The GA733 antigen, as defined by MAbs GA733 and
C017-lA, is expressed primarily by carcinomas of the digestive
tract and, less frequently, by carcinomas of the breast, lung and
ovary (Gottlinger et al, 1986; Shetye et al, 1988). It is also
expressed on some normal epithelial tissues (Gottlinger et al,
1986; Shetye et al, 1988). Immunoscintigraphy studies with radio-
labelled MAb CO17-lA in colorectal cancer patients (Mach et al,
1983), as well as ex vivo perfusion ofpatients' tumour-containing
colon segments with the MAb (Sears et al, 1981), have demon-
strated preferential localization ofthe antigen on tumour vs normal
tissues.
The GA733 antigen has shown promise as a target in
approaches to passive immunotherapy of colorectal cancer
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patients with MAbs CO17-1A (Sears et al, 1984; Frodin et al,
1988; Lobuglio et al, 1988; Riethmuller et al, 1994) and GA733
(Herlyn et al, 1991). Patients treated with MAb CO17-lA in a
phase II randomized trial demonstrated significantly decreased
recurrence and death rates compared with untreated control
patients (Riethmuller et al, 1994). Active immunotherapy with
anti-idiotypic antibodies mimicking the CO17-lA or GA733
epitopes has shown promise in the treatment of colorectal cancer
patients (Herlyn et al, 1987, 1994; Somasundaram et al, 1995).
With the availability, for active immunotherapy, of the recombi-
nant GA733 antigen expressing multiple potentially immunogenic
epitopes (Strassburg et al, 1991; Herlyn et al, 1995, 1997), a rele-
vant animal model for experimental immunotherapy that targets
this antigen has become increasingly important. Such a model
should allow testing of induction of immunity and of possible
toxicity and should take into account the frequently observed
immunological tolerance of cancer patients against antigens,
including GA733, expressed by their growing tumours (Hamby
et al, 1987; Wettendorif et al, 1989). This tolerance has been
related to the immunological cross-reactivity oftumour-associated
antigen with normal tissue antigen, resulting in immune suppres-
sion. Thus, in the ideal animal model of active immunotherapy
against human tumour-associated antigens, the human antigen or a
closely related homologue should be expressed on normal animal
tissues. Such a model will also allow the evaluation of potential
adverse side-effects induced by targeting the antigen/homologue
on normal animal tissues.
A murine cDNA with striking homology in the nucleotide (80%
in the coding region) and predicted amino acid (82%) sequences to
the human GA733 sequences has been described (Bergsagel et al,
1992). (The human and murine loci have been designated MlSlh
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and MIS1 by the International Committee on Genomic
Nomenclature in the human and murine genomic databases
respectively.) The murine mRNA is expressed in normal murine
epithelial tissues, with a tissue distribution similar to that of the
GA733 antigen in humans (Herlyn et al, 1984; Gottlinger et al,
1986; Shetye et al, 1988; Bergsagel et al, 1992). However, the
expression of the protein that includes the therapeutically impor-
tant CO17-lA and GA733 epitopes in various murine tissues and
tissues of other experimental animals, including non-human
primates, and that may provide model systems for immunotherapy
targeting the human GA733 antigen is unknown. These analyses
are essential to evaluate critically the relevance of preclinical
studies of immunotherapy against the human GA733 antigen for
clinical trials in patients.
We describe here our survey of various tissues from mice, rats,
rabbits and non-human primates for the expression of the protein
of the GA733 antigen homologue, using both monoclonal and
polyclonal antibodies to the human GA733 antigen for detection.
Immunological cross-reactivity between the human GA733
antigen and the murine antigen homologue [murine epithelial
glycoprotein (mEGP); Bergsagel et al, 1992] was further investi-
gatedusing these proteins derived from recombinant baculoviruses.
MATERIALS AND METHODS
Animals
Three-month-old female BALB/c and CBA mice, 6-month-
old female Sprague-Dawley rats (Harlan-Sprague-Dawley,
Indianapolis, IN, USA), 6-month-old female New Zealand White
rabbits (Hare Marland, Hewitt, NJ, USA) and two adult male
baboons (Papio cynomolgus) raised at the Southwest Foundation
for Biomedical Research (San Antonio, TX, USA) were used as
sources oftissues.
Tissues and cell lines
Table 1 lists the various tissues obtained from mice, rats, rabbits
andbaboons. All tissues were fixed in 10% buffered formaldehyde
and embedded into paraffin blocks. The human colorectal carci-
nomacell line SWI116 and the gastric carcinoma cell line Kato III
were obtained from the American Type Culture Collection
(Rockville, MD, USA).
Antibodies
MAbs CO17-lA and GA733 (Herlyn et al, 1979, 1984; Gottlinger
et al, 1986) were purified from ascites on protein A-agarose
columns. Forproduction ofrabbit polyclonal antibodies to GA733
antigen, rabbits were immunized with the antigen purified from
Nonidet P40 extracts ofthe human colon carcinoma cells SWi116
on immunoaffinity columns coupled with MAb GA733 (Ross et
al, 1986). Rabbits were immunized subcutaneously three times
with 31,g (first injection) of antigen in Freund's complete adju-
vant and 15.5 gg (second and third injections) ofantigen in incom-
plete adjuvant. These polyclonal antibodies contain antibodies
directed to the epitopes defined by MAbs GA733 and C017-IA
on the antigen, based on the demonstrated inhibition (49-65%) of
binding of the MAbs defining these epitopes to colorectal carci-
noma cells by the rabbit polyclonal antibodies to GA733 antigen
but not by normal rabbit IgG (results not shown).
Table 1 Expression of the GA733 antigen homologue on normal animal
tissues as detected by rabbit polyclonal antibodies to the GA733 antigen
Animal species
Tissue Mousea Ratb Rabbitc Baboond
Oesophagus
Stomach
Small intestine + + - +
Colon
Columnar cells + + - +
Goblet cells - - - +
Rectum + + - ND
Liver (+) (+) - (+)
Bile duct - - - +
Pancreas
Thyroid
Kidney
Spleen
Lung
Brain
Skin
aThree BALB/c, one CBA mice. bThree Sprague-Dawley rats. cThree New
Zealand white rabbits. dTwo Papio cynomolgus baboons. Identical results
were obtained with different animals derived from the same species.
+, Tissues stained positive; (+), tissues stained weakly positive only in biliary
ducts in the portal tract; -, tissues stained negative; ND, not determined.
For production of rabbit polyclonal antibodies to the extra-
cellular domain of mEGP (mEGP-EC) antigen, rabbits were
immunized subcutaneously with 52 jg of recombinant antigen
(for production and purification of the antigen, see below) in
Freund's complete adjuvant (first injection) and 16 jg of antigen
in incomplete adjuvant (second and third injections). Antibodies
were isolated from immune rabbit sera on protein A-agarose
columns. Normal murine and rabbit immunoglobulins (Organon
Teknika, Durham, NC, USA) were used as negative controls.
All antibodies were dialysed against 0.1 M sodium bicarborate,
pH 8.2-8.6, and incubated with biotin (120 jg of NHS-LC-biotin
per 1 mg of antibody; Pierce Chemical, Rockford, IL, USA) in
dimethylsulphoxide (DMSO) for 4 h at room temperature. The
labelled antibody preparations were then dialysed against phos-
phate-buffered saline (PBS). Biotinylated rabbit polyclonal anti-
bodies to GA733 antigen and MAb GA733 all bound specifically
to their corresponding antigens in enzyme-linked immunosorbent
assay (ELISA). However, MAb C017-IA lost its binding reac-
tivity to GA733 antigen afterbiotinylation and was not included in
the immunoperoxidase assays.
Direct immunohistoperoxidase method
Four serial sections from each tissue sample were deparaffinized,
rehydrated, washed and incubated with 3% hydrogen peroxide in
methanol for 15 min to block endogenous peroxidase. Sections
were then washed with PBS and incubated overnight at 4°C with a
1:10 dilution of normal mouse serum (for staining with biotiny-
lated MAb) or normal rabbit serum (for staining with biotinylated
rabbit antibodies). Sections were further incubated with the
various preparations of biotinylated antibodies at 100 jg ml-'
for 1 h at room temperature, washed and incubated with
avidin-peroxidase complex (ABC VectaStain Reagent Kit, Vector,
Burlingame, CA, USA) for 1 hatroomtemperature. Theperoxidase
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reaction was developed with diaminobenzidine (5 mg in 10 ml of
PBS containing 10gl of 30% hydrogen peroxide) for 3 min at
room temperature. Sections were washed, counterstained with
haematoxylin/eosin, dehydrated and mounted according to
standard procedures.
Immunoprecipitation
Single-cell suspensions were prepared from various BALB/c mouse
tissues or Kato III human gastric carcinoma cells. Cells in suspen-
sion (5 x 107 cells in 10 ml of isotonic Tris buffer, pH 7.5) were
biotinylated (NHS-LC-biotin, 100gl of 10 mg ml-' stock DMSO,
Pierce Chemical, Rockford, IL, USA) to label cell-surface mole-
cules. Aliquots ofthe cells were lysed in RIPA buffer [20 mm Tris-
HCI, pH 8.5, 150 mm sodium chloride, 5 mm EDTA, 1% Triton
X-100, 1% deoxycholic acid, 0.1% sodiumdodecyl sulphate (SDS),
1 mm phenylmethylsulphonyl fluoride (PMSF)] and centrifuged,
and the supernatants were incubated with protein A-Sepharose
beads to remove non-specifically boundmaterial. Supernatants were
then incubated overnight with protein A-Sepharose beads coupled
with antibody (1:40 serum dilution or 400-800jg ml-' of MAb
C017-IA or GA733). After six washes with RIPA buffer, samples
were boiled in 50gl of SDS-polyacrylamide gel electrophoresis
(PAGE) sample buffer for 3 min and centrifuged, and 25 gl of the
supematant was separated on a 12% SDS-PAGE and transferred to
nitrocellulose. The blot was blocked [3% bovine serum albumin
(BSA) in 50 mM Tris-HCl, pH 7.5, 500 mm sodium chloride, 0.1%
Tween-20], incubated with alkaline phosphatase-conjugated strepta-
vidin (1:5000, Sigma ImmunoChemicals, St Louis, MO, USA) and
developed with substrate solution.
Recombinant mEGP-EC production
Oligonucleotide primers were synthesized by automated
phosphoramidite chemistry on a model 380A DNA synthesizer
(Applied Biosystems, Foster City, CA, USA). mEGP-EC was
amplified by polymerase chain reaction (PCR) from mEGP cDNA
template (1 ng) (Bergsagel et al, 1992). A 795-bp product was
generated using PCR primers containing a PstI site (5' end, bp
108) (Isberg and Leong, 1990) and a XbaI site and translation stop
codon (3' end, bp 902) (Sommers and Smith, 1987). The produc-
tion of the transfer vector and, subsequently, of mEGP-EC was
essentially the same as that described for the human GA733
antigen (Strassburg et al, 1991). Briefly, the baculovirus vector
pVL1392 containing the 796-bp fragment coding for the EC of
mEGP was constructed by unidirectional cloning ofthe mEGP-EC
cDNA into the XbaI-PstI site. Sequencing of mEGP-EC
subcloned from the pVL1392 recombinant into pUC-19 confirmed
identity with the published mEGP sequence (Bergsagel et al,
1992). The recombinant baculovirus vector and Baculogold viral
DNA (Pharmingen, San Diego, CA, USA) were cotransfected into
Sf9 insect cells (Sommers and Smith, 1987) grown in Grace's
insect cell medium (Gibco, BRL, Gaithersburg, MD, USA)
supplemented with 10% fetal bovine serum to obtain recombinant
baculovirus mEGP-EC. Recombinant virus from culture super-
natant (passage 1) was used to infect High-Five insect cells
(Invitrogen Corporation, San Diego, CA, USA) to produce
passage 2 virus stocks. The passage 2-infected cells were grown in
serum-free medium (SF900, II; Gibco, BRL) for 72 h. A sample
of the culture supernatant (containing secreted mEGP-EC)
was subjected to SDS-PAGE, and the gel was stained with
Coomassie blue. Secreted mEGP-EC was purified from culture
supernatant on a Mono-Q column (Pharmacia, Uppsala, Sweden)
following the manufacturer's procedure. Protein concentration in
the purified antigen preparation was determined using the method
ofLowry et al (1951).
ELISA
Binding reactivities between recombinant proteins and antibodies
were determined by ELISA (Somasundaram et al, 1995). Briefly,
ELISA plates (Coming Glass Works, Coming, NY, USA) were
coated with different amounts ofantigen (GA733-EC, mEGP-EC or
BSA) overnight at 4°C, blocked, washed and treated with various
dilutions of polyclonal rabbit anti-mEGP-EC or anti-GA733-EC
antibodies, MAb to GA733 antigen or control antibodies. After
incubation, plates were washed and peroxidase-labelled secondary
antibodies (goat anti-mouse F(ab')2 or anti-rabbit IgG; Accurate
Chemical and Scientific, Westbury, NY, USA) were added for 1 h at
room temperature. Plates were washed and ABTS Microwell perox-
idase substrate (Kirkegaard & Perry Labs, Gaithersburg, MD, USA)
was added. Reactions were terminated by addition of0.5 M sodium
hydroxide, and optical density (OD) at405 nm was determined.
RESULTS
Reactivities of tissues from experimental animals with
polyclonal rabbit antibodies to the GA733 antigen in
immunohistoperoxidase assay
Table 1 summarizes the distribution of the GA733 antigen homo-
logue on various animal tissues as detected by polyclonal rabbit
antibodies to the human antigen in the immunohistoperoxidase
assay. The intestinal mucosa was stained in mice, rats and non-
human primates but not in rabbits. In addition, the liver of mice,
rats and non-human primates reacted weakly, but specifically, with
polyclonal antibodies to the GA733 antigen, in particular in biliary
ducts in the portal tract. Baboons also expressed the antigen on the
distal part of the common bile duct. Apical staining of columnar
cells of the mucosa was predominant in the intestine of mice, rats
and baboons (Figures 1-3 respectively). In baboons, the goblet
cells ofthe mucosa also showed clearreactivity (Figure 3), similar
to the findings in human intestine (Figure 4). Secreted mucins
were strongly positive in mouse, baboon and human tissues
(Figures 1, 3 and 4) but weakly positive in rat tissues (Figure 2).
Despite these differences, the common feature of antigen
expression in normal tissues of mice, rats, non-human primates
and humans is the presence of the antigen in intestinal mucosa
from duodenum to lower rectum.
Non-reactivity of tissues of experimental animals with
MAb to the GA733 antigen
None of the tissues that were derived from the various animal
species and that were reactive with polyclonal antibodies to
GA733 (Table 1) were positive forthe epitope definedby the MAb
GA733 (not shown), which was detected in human colonic tissue
(Figure 5), in agreement with our previous results (Herlyn et al,
1984). In normal human colon, MAb GA733 stained only the basal
parts of columnar cells, mostly in upper, differentiated parts of
intestinal crypts or villi (Figure 5), whereas polyclonal antibodies
also stained goblet cells and secreted mucins (Figure 4).
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Figure 1 Expression of the GA733 antigen homologue in normal colon of a
BALB/c mouse. (A) Direct immunoperoxidase staining with biotinylated
polyclonal rabbit antibodies to the GA733 antigen. (B) Absence of staining
with biotinylated normal rabbit IgG (x 160 magnification; haematoxylin/eosin
counterstain)
Immunoprecipitation of the GA733 antigen homologue
from normal mouse tissues with polyclonal antibodies
to mEGP-EC or GA733 antigen
Using rabbit polyclonal antibodies to mEGP-EC, a40-kDa antigen
was precipitated from mouse colon (Figure 6, lane c), normal
mouse small intestine, stomach, kidney and lung tissues but not
from any other normal tissues tested (Table 2). These immunopre-
cipitation data correlate well with results obtained previously by
Northern blotting (Bergsagel et al, 1992). A 40-kDa antigen was
also precipitated with rabbit polyclonal antibodies to GA733
antigen from both Kato III human gastric carcinoma cells (Figure6,
lane a) and normal mouse colon (Figure 6, lane b) and intestine but
not from any other tissues tested (Table 2). These antibodies non-
specifically precipitated two minor higher molecular weight con-
taminants from normal mouse colon (Figure 6, lanes b and d).
Rabbit anti-BSA antibody precipitated neither the human GA733
antigen from Kato III cells (not shown) nor the 40-kDa GA733
antigen homologue from normal mouse intestine (Figure 6, lane
d). MAbs GA733 and CO17-lA precipitated the antigen from
Kato III cells but not from normal mouse colon. Furthermore, the
antigen homologue could not be isolated from NP-40 extracts of
normal mouse colon on immunoaffinity columns coupled with
Figure 2 Expression of the GA733 antigen homologue in normal colon of a
Sprague-Dawley rat. For A and B, see Figure 1 legend (x 160 magnification;
haematoxylin/eosin counterstain)
MAb GA733 or C017-IA (not shown). The molecular mass
(40 kDa) estimated for the immunoprecipitated murine antigen
by SDS-PAGE is consistent with the estimated molecular mass
(37.4kDa) based on thededuced amino acid sequence ofthe mature
protein and the assumption that each ofthe two potential glycosyla-
tion sites has a 5-kDa sugar moiety (Bergsagel et al, 1992).
Immunological cross-reactivity between human GA733
antigen and mEGP-EC derived from recombinant
baculovirus
To demonstrate immunological cross-reactivity between isolated
human GA733 and mEGP proteins, the reactivity of recombinant
baculovirus-derived GA733-EC (Strassburg et al, 1991) with poly-
clonal antibodies to mEGP-EC and baculovirus-derived mEGP-
EC (described below) with either polyclonal or monoclonal
antibodies to GA733-EC was determined.
Supernatants of High-Five cells infected with recombinant
baculovirus mEGP-EC were monitored by SDS-PAGE to evaluate
expression and secretion of mEGP-EC purified on an anion
exchange column. Purified mEGP-EC protein migrated on SDS-
PAGE with an apparent mass of about 33 kDa (Figure 7, lane c),
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Figure 3 Expression of the GA733 antigen homologue in normal colon of a
baboon. For A and B, see Figure 1 legend (x 160 magnification;
haematoxylin/eosin counterstain)
which is similar to the apparent size of the GA733-EC expressed
in insect cells and purified by immunoaffinity chromatography on
MAb GA733-coupled Sepharose (Strassburg et al, 1991; Figure 7,
lane b). Both proteins are heterogeneously glycosylated, which is
probably responsible for their migration as diffuse bands on SDS
gels at a somewhat higher apparent molecular mass compared with
the actual size.
Direct analysis of purified mEGP-EC by MALDI mass spec-
trometry showed substantial mass heterogeneity, with a predomi-
nant mass at about 28 496 Da. The difference between this
observed mass and the predicted mass of 27 712 Da calculated
from the amino acid sequence after signal peptide removal prob-
ably results from glycosylation. This mass difference and the
observed heterogeneity of mEGP-EC are similar to the hetero-
geneity obtained forboth the full-length and extracellular forms of
the GA733 antigen using mass spectrometry (data not shown). The
discrepancy between the actual mass of mEGP-EC of about
28.5 kDa determined by mass spectrometry and the apparent mass
ofabout 33 kDa on SDS gels reflects anomalous protein migration
on the gels, as is typically observed for glycoproteins.
Recombinant mEGP-EC was used as a target forpolyclonal and
monoclonal antibodies to the human GA733 antigen in ELISA.
For comparison, human GA733 antigen was used as a target for
polyclonal antibodies to mEGP-EC. Polyclonal rabbit antibodies,
Figure 4 Expression of the GA733 antigen by normal human colon. For A
and B, see Figure 1 legend (x 160 magnification; haematoxylin/eosin
counterstain)
but not MAb GA733 or C017-lA, to the human GA733 antigen
showed significant and specific binding to purified recombinant
mEGP-EC (Table 3). Binding of polyclonal anti-GA733 anti-
bodies to mEGP-EC was lowerthan thatofpolyclonal anti-mEGP-
EC antibodies to mEGP-EC. Polyclonal anti-mEGP-EC antibodies
also bound significantly to the human antigen, although at lower
levels than the antibodies elicited by the human antigen (Table 3).
DISCUSSION
The human colorectal carcinoma-associated antigen GA733
expressed on both tumour and normal tissues is one of the
best studied targets for experimental and clinical cancer
immunotherapy. However, the relevance of preclinical studies of
targeting this antigen in passive and active immunotherapy (with
MAbs, anti-idiotypic antibodies, and recombinant antigen;
reviewed in Herlyn et al, 1982, 1995, 1996) for clinical trials in
patients has been difficult to determine in the absence of informa-
tion on normal tissue expression of the antigen homologue in
animals. We demonstrate here that an antigen homologous to the
human gastrointestinal carcinoma-associated antigen GA733 is
expressed by normal intestine and liver of mice, rats and non-
humanprimates, as determined by immunohistoperoxidase staining
of tissues. The common feature of GA733 antigen homologue
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immunoprecipitation and Northern blot analysis
lmmunoprecipitationa
Anti-mEGP-EC Anti-GA733 Northern
Tissue antibody antibody blottingb
Stomach + - +
Small intestine + + +
Colon + + +
Kidney + - +
Lung + - +
Heart - - -
Muscle - - -
Liver - - -
Brain - - -
Spleen - - -
B
Figure 5 Expression of the GA733 epitope in human colon tissue. Tissue
was stained with biotinylated MAb GA733 (A) or normal mouse
immunoglobulin (B) in direct immunoperoxidase assay (x 160 magnification;
haematoxylin/eosin counterstain)
Mr(X1 Y)
,97
-66
-45
31
-21
-14
a b c d
Figure 6 Immunoprecipitation of the GA733 antigen from human gastric
carcinoma cells Kato Ill (lane a) and of the antigen homologue from normal
murine colon tissue (lanes b and c). Equivalents of 6.25 x 106 cells were
loaded per lane. Antibodies: lanes a and b, rabbit sera to the GA733 antigen;
lane c, rabbit sera to mEGP; lane d, rabbit sera to BSA. Nitrocellulose
immunoblot was developed with alkaline phosphatase-labelled streptavidin
and substrate. Molecular size (M,) markers were run in an adjacent lane
almmunoprecipitation of mEGP with rabbit anti-mEGP-EC or anti-GA733
antigen sera was performed as described in Materials and methods. Control
antibodies (rabbit anti-BSA) showed no reactivity. bBergsagel et al (1992).
Mr(X103) - ~~~~~~~~~~~~~~~.
-97
69
-46
-30
-21.5
a b c
Figure 7 SDS-PAGE of recombinant GA733-EC and mEGP-EC. Purified
recombinant proteins were subjected to SDS-PAGE on a 10% gel in the
absence of reducing reagents, and the gel was stained with Coomassie blue.
Molecular size markers were run in the right lane. (a) Full-length
recombinant GA733 antigen (8 gig), (b) GA733-EC (4 gig) and (c) mEGP-EC
(4 jig). The full-length GA733 recombinant protein showed a major monomer
band and a minor dimer band
expression in normal animal tissues is its presence in intestinal
secretions and mucosa from duodenum to lower rectum. Staining
of additional cell types of intestine with polyclonal antibodies to
human GA733 antigen varied somewhat for the different species
and may reflect species differences in the cellular distribution
of various antigenic epitopes of the antigen homologue.
Alternatively, more than one gene may regulate expression of the
various epitopes recognized by the polyclonal antibodies.
SDS-PAGE analyses with polyclonal antibodies to mEGP-EC
revealed the expression of the antigen homologue in mouse intestine,
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Table 3 Immunological cross-reactivity between the human GA733-EC and
mEGP-EC
Antibody binding (OD at 405 nm)
Antibodya mEGP-EC GA733-EC
Rabbit aGA733-EC antigen 0.301b 0.438b
Rabbit amEGP-EC 0.471b 0.299b
MAb GA733 0.016 0.390b
MAb C017-1A 0 0.240b
Normal rabbit IgG 0.028 0.034
Normal mouse IgG 0.016 0.039
aAntibodies were used at optimal concentrations (2-10 tgg ml-') showing
maximal binding values in ELISA. bValues are significantly higher (P< 0.05;
Student's t-test) than control values (obtained with normal IgG on specific
target or immune IgG on BSA target).
stomach, lung and kidney tissues. These tissues express mEGP
RNA (Bergsagel et al, 1992). However, the antigen was not
detected on these tissues (with the exception of intestine) by
immunoprecipitation or by immunohistoperoxidase staining with
polyclonal antibodies to human GA733. Thus, the murine antigen
homologue can be detected in normal mouse intestine by anti-
bodies directed to both the murine and human antigen, whereas its
detection in normal mouse stomach, lung and kidney tissues is
restricted to antibodies directed to the murine antigen. These
differences most likely reflect the greater sensitivity of antigen
detection using the homologous compared with the heterologous
antibody. Therefore, it is possible that in rats and baboons, similar
to mice, tissues in addition to intestine and liver found positive in
immunohistoperoxidase assay with antibodies to the human
GA733 antigen express the antigen homologue; although it is diffi-
cult to test this hypothesis as antibodies to the rat and baboon
antigen homologues are not available.
mEGP and the rat and baboon antigen homologues might be
expressed at low levels in the liver, in particular in biliary ducts in
the portal tract, as determined in immunohistoperoxidase assay;
but these results could not be confirmed by immunoprecipitation
of mouse liver tissues with antibodies to mEGP-EC, in addition
mEGP mRNA is absent in these tissues (Bergsagel et al, 1992).
The expression of the antigen in a small subset of liver cells may
render its detection by immunoprecipitation and Northern blotting
difficult.
Expression of the GA733 antigen homologue mEGP in normal
mouse tissues is consistent with the previous description of a
murine cDNA with -80% sequence homology (in the coding
region) to the human GA733 cDNA (Bergsagel et al, 1992);
however, their study did not investigate the expression of the
antigen by normal mouse tissues. Importantly, we have provided
direct evidence for the immunological cross-reactivity between
mEGP and the human GA733 antigen. Thus, polyclonal antibodies
to the human antigen bound specifically to murine intestinal tissue.
Furthermore, recombinant mEGP-EC protein bound to antibodies
elicited by the human GA733 antigen, and GA733 antigen bound
to antibodies elicited by mEGP-EC.
In mice, the CO17-lA epitope was absent in immunoprecipita-
tion and immunoaffinity antigen isolation analyses of normal
intestinal tissue. Furthermore, in mice, rats and non-human
primates, immunohistoperoxidase staining of normal tissues did
not detect the epitope defined by MAb GA733, although this
epitope is expressed by human tissues (Herlyn et al, 1984). In
contrast, Shetye et al (1990) have reported the staining of normal
colonic and pancreatic tissues with MAb GA733 in rats. This
discrepancy may be a result of the different detection methods
used, i.e. direct immunohistoperoxidase assay with purified MAb
in the present study vs indirect assay with MAb in tissue culture
supernatant in the study by Shetye et al (1990). We used the direct
assay using biotinylated MAb to the GA733 antigen because ofits
high specificity. The indirect assay, in which we used sequentially
unlabelled, purified MAb and labelled anti-mouse immunoglob-
ulin antibody, did notreveal specific binding ofMAb GA733 to rat
tissues because of high non-specific binding of control mouse
immunoglobulin (results not shown).
The absence of the GA733 and C017-lA epitopes on normal
mouse tissues is consistent with the demonstrated absence ofthese
epitopes on baculovirus-derived mEGP-EC. Furthermore, the
GA733 epitope is absent on murine plasmacytoma cells, despite
the presence of mEGP mRNA in these cells (Bergsagel et al,
1992). Given that the GA733 and CO17-lA epitopes are absent on
animal tissues, we speculate that in humans these epitopes are
encoded by those sequences in the human GA733 antigen
(residues 3-45 or 150-186) that differ from the corresponding
sequences ofthe murine antigen homologue.
Thus, the antigen identified in animal tissues by the rabbit poly-
clonal antibodies is similar, but not identical, to the human GA733
antigen, and both antigens show similartissue distribution (Herlyn
et al, 1984; Gottlinger et al, 1986; Shetye et al, 1988).
The non-reactivity of rabbit tissues with rabbit polyclonal anti-
bodies to the human GA733 antigen might reflect the presence of
antibodies in the polyclonal preparation directed preferentially to
epitopes that are absent on normal rabbit tissues. Thus, rabbits
might be immunologically tolerant ofthose epitopes on the human
antigen that are also expressed on normal rabbit tissues.
Alternatively, rabbits might not express any GA733 antigen-
related epitopes on their normal tissues, although this seems
unlikely in light ofthe wide distribution ofthe antigen homologue
in other animal species.
We have shown that mice, rats and non-human primates express
the GA733 antigen homologue that lacks the C017-lA and
GA733 epitopes on some oftheir normal tissues. Previous studies
of experimental passive and active immunotherapy targeting the
human GA733 antigen in mice (Herlyn et al, 1982, 1984, 1995,
1997) must be interpreted with caution, keeping in mind the
immunological differences between the human antigen and its
homologue. Thus, passive immunotherapy with MAb C017-lA
and GA733 (Herlyn et al, 1982, 1984) and active immunotherapy
with anti-idiotypic antibodies mimicking the GA733 or C017-IA
epitope or with recombinant GA733 antigen (reviewed in Herlyn
et al, 1995, 1996) have been performed in mice which, in contrast
to humans, do not express the C017-lA and GA733 epitopes on
normal tissues. The differences in the GA733 epitope tissue
expression between mice and humans might explain why treat-
ment of mice with MAb GA733 was not accompanied by toxicity
(Herlyn et al, 1984), whereas this MAb showed dose-limiting toxi-
city to gastrointestinal organs in colon cancer patients (Herlyn et
al, 1991). Recently, MAb G8.8 against mEGP has been described
(Farr et al, 1991; Borkowski et al, 1996). The MAb binds to
various murine epithelial tissues (Farr et al, 1991), and thus it
provides a valuable tool for experimental passive and active
immunotherapy against mEGP using the MAb and derived anti-
idiotypic antibodies respectively. Furthermore, our initial studies
of active immunotherapy in mice, using recombinant human
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GA733 antigen derived from baculovirus or expressed in vaccinia
or adenovirus (Herlyn et al, 1995), must be followed by similar
studies using recombinant mEGP vaccines. We are currently
developing a murine model of active immunotherapy against
mEGP that includes the well-characterized murine colon carci-
noma cell line CT26 (Brattain et al, 1980). This model closely
mimics the conditions in patients and thus may be predictive for
future clinical trials ofactive immunotherapy targeting the GA733
antigen.
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